MME Paule HARDY

Rhumatologue

SalariéRPPS 10001836187

📊 Reconnaissance scientifique : 3/100📝 5 articles publiés🇫🇷 Publications académiques françaises (1)

✨ Profil synthétique

IA · 19/05/2026

MME Paule HARDY est une rhumatologue salariée avec des intérêts de recherche variés, notamment les troubles parathyroïdiens, la santé osseuse et les tendinopathies. Elle a publié 5 articles et possède un h-index de 3 selon OpenAlex. Ses publications sur PubMed couvrent des sujets tels que l'ostéoporose, la pharmacovigilance et l'imagerie par résonance magnétique ostéo-articulaire.

Expertises présumées

Tendinopathies
Ostéoporose
IRM ostéo-articulaire
Pharmacovigilance
Troubles parathyroïdiens
Santé osseuse
Essais cliniques

Synthèse automatique à partir des sources publiques (HAL, OpenAlex, theses.fr, ClinicalTrials.gov, FAI²R, ANS). Pas une évaluation clinique. Le médecin peut corriger via son compte.

✨ Génération du profil synthétique IA en cours…

Activité de recherche & publications

Indicateurs publics agrégés sur 250 M+ d'œuvres scientifiques (OpenAlex, PubMed). Traduits ici en langage patient.

Influence scientifique

3 articles ont été cités au moins 3fois par d'autres chercheurs — preuve que ses travaux sont repris par la communauté médicale.

Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.

Top publications · les plus citées

Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study

Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 1997

📚 224 citations🎯 RCR 6.19Top 6% NIH🩺 Clinique

Lire l'abstract Crossref ↓

PURPOSE To determine the effectiveness and safety of the bisphosphonate risedronate in preventing bone loss in young women with breast cancer and early menopause induced by chemotherapy who are at major risk for the development of postmenopausal osteoporosis. PATIENTS AND METHODS Fifty-three white women, aged 36 to 55 years, with breast cancer and artificially induced menopause were stratified according to prior tamoxifen use. Thirty-six patients received tamoxifen (20 mg/d). Within each stratum, patients were randomly assigned to receive risedronate (n = 27) or placebo (n = 26). Treatment consisted of eight cycles oral risedronate 30 mg/d or placebo daily for 2 weeks followed by 10 weeks of no drug (12 weeks per cycle). Patients were monitored for a third year without treatment. RESULTS Main outcomes of the study were changes in lumbar spine and proximal femur (femoral neck, trochanter, and Ward's triangle) bone mineral density (BMD), and biochemical markers of bone turnover. In contrast to a significant decrease of BMD at the lumbar spine and hip in the placebo group, there was an increase in BMD in the risedronate group. On treatment withdrawal, bone loss ensued, which suggests that treatment needs to be continuous to maintain a protective effect on bone mass. At 2 years, the mean difference (+/- SEM) between groups was 2.5% +/- 1.2%, (95% confidence interval [CI], 0.2 to 4.9) at the lumbar spine (P = .041) and 2.6% +/- 1.1%, (95% CI, 0.3 to 4.8) at the femoral neck (P = .029). Similar results were observed at the hip trochanter. Results by stratum indicate a beneficial, although partial, effect of tamoxifen in reducing bone loss. Risedronate was well tolerated and showed a good safety profile, with no evidence of laboratory abnormalities. CONCLUSION Risedronate appears to be a safe treatment that prevents both trabecular and cortical bone loss in women with menopause induced by chemotherapy for breast cancer.

Quality of life and psychological status in patients with primary Sjögren's syndrome and sicca symptoms without autoimmune features

Arthritis and rheumatism · 2006

📚 79 citations🎯 RCR 2.88Top 17% NIH

Lire l'abstract Crossref ↓

AbstractObjectiveTo compare pain, fatigue, and sicca symptoms; quality of life; and psychological status between patients with primary Sjögren's syndrome (SS) and those with sicca symptoms but no autoimmune features (sicca asthenia polyalgia syndrome [SAPS]), and to determine whether a psychological pattern can be detected in patients with SAPS, which could suggest psychological distress as the cause.MethodsThis cross‐sectional, prospective study included 111 patients with primary SS according to the American‐European Consensus Group criteria and 65 SAPS patients with no focus on lip biopsy and no anti‐SSA/SSB antibodies. Pain, fatigue, and sicca symptoms were assessed using visual analog scales; quality of life was assessed using the Short Form 36 (SF‐36); and psychological distress by the Symptom Checklist‐90‐Revised (SCL‐90‐R) questionnaire.ResultsNo difference was observed between primary SS and SAPS patients for pain, fatigue, sicca symptoms, quality of life, and psychological status. Fatigue and pain, but not dryness, were correlated with both quality of life and psychological distress in both groups. For primary SS patients, physical and mental composite scores on the SF‐36 correlated well with global severity index (GSI) scores of the SCL‐90‐R (r = −0.29, P = 0.006 and r = −0.61, P < 0.0001, respectively).ConclusionPatients with primary SS and SAPS do not differ in quality of life or psychological status. Although both diseases probably have a different origin, they may require the same psychological support or psychiatric care. The strong correlation between the composite physical and mental scores of the SF‐36 and the GSI scores of the SCL‐90‐R in primary SS patients emphasizes the importance of the psychological dimension in results of the SF‐36.

Arthroplasty following a septic arthritis history: a 53 cases series

Orthopaedics & traumatology, surgery & research : OTSR · 2010

📚 65 citations🎯 RCR 3.15Top 15% NIH

Cookies & analyse de trafic

MME Paule HARDY

Pourquoi vous devez consulter ce praticien

Activité de recherche & publications

Publications académiques en France

Lieu de consultation

Tarifs & secteur de conventionnement

Prendre rendez-vous & contact

Top publications · les plus citées

Publications scientifiques (32) — classées par pathologie

Transversal24

Tendinopathies & SCC3

Essai clinique1

IRM ostéo-articulaire1

Ostéoporose1

Pharmacovigilance1

Revue générale1

Sjögren1

Partager cette fiche